The US Food and Drug Administration (FDA) has accepted for review the supplemental biologics license application (sBLA) for Sanofi and Regeneron’s Dupixent (dupilumab) to treat chronic spontaneous urticaria (CSU) in adults and children aged 12 and above, particularly for those whose condition persists despite H1 antihistamine treatment.
Investors participating in the round included VI Partners via the Venture Incubator fund and Zürcher Kantonalbank. The proceeds will be used to progress a drug candidate from Inositec’s
The phase III randomized, double-blind, parallel arm, multiple dose, active comparator study also met secondary endpoints. The study included 645 patients diagnosed with moderate to severe active RA
Patients who received apatorsen treatment experienced a 20% reduction in risk of death, compared to patients receiving docetaxel alone (HR=.80; 95% CI: 0.65-0.98; p=0.078). The primary analysis was
Professor Eicke Latz, Director of the Institute, and Professor Matthias Geyer, Department Head for Structural Immunology, are scientific Co-founders of IFM Therapeutics. IFM Therapeutics’ scientific mission is to
Betrixaban, an FDA Fast Track-designated investigational drug, is an oral, once-daily Factor Xa inhibitor anticoagulant. John Curnutte, M.D. Ph.D., executive vice president, research and development at Portola, said:
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.
